The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Azenosertib plus paclitaxel for platinum-resistant ovarian cancer: Results from a phase 1b study.
 
Meena Okera
Consulting or Advisory Role - Lilly
Speakers' Bureau - AstraZeneca; Novartis
 
Catherine Shannon
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Daiichi Sankyo/Lilly; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Merck; Merck sharp and Dohme; Novartis; Novartis; Roche
Speakers' Bureau - Amgen; AstraZeneca; AstraZeneca; AstraZeneca; Gilead Sciences; GlaxoSmithKline; GlaxoSmithKline; Lilly; Merck; merk sharp & Dohme; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis
 
Gary Richardson
Research Funding - Adagene (Inst); Agenus (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Thera Solutions (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); ChemoCentryx (Inst); Corvus Pharmaceuticals (Inst); Curon Biopharmaceutical (Inst); D3 Bio (Inst); D3 Bio (Wuxi) Co., Ltd. (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Fosun Pharma (Inst); Gene Quantum (Inst); Genfleet Therapeutics (Inst); ImmunGen Inc (Inst); Imugene (Inst); InventisBio (Inst); Janssen Oncology (Inst); Keythera Pharmaceuticals (Inst); LaNova Australia (Inst); Medicenna (Inst); Merck (Inst); Minghui Pharmaceutical (Inst); Neoleukin Therapeutics (Inst); Novotech (Inst); Pfizer (Inst); PharmAbcine (Inst); RemeGen (Inst); Roche/Genentech (Inst); Seagen (Inst); Senz Oncology (Inst); Shanghai Henlius Biotech (Inst); Shanghai Henlius Biotech (Inst); Surface Oncology (Inst); Suzhou Alphamab (Inst); Takeda (Inst); Therapim (Inst); Zentalis (Inst)
 
Siqing Fu
Research Funding - Abbisko (Inst); Antengene (Inst); BeiGene (Inst); BeyondSpring Pharmaceuticals (Inst); Biotheus (Inst); Boehringer Ingelheim (Inst); Clinical and Translational Science Award Grant (CTSA) 1UM1TR0045906 (Inst); Coherent Biopharma (Inst); CPRIT Precision Oncology Decision Support Core (RP150535) (Inst); Crossignal (Inst); CUE Biopharma (Inst); DEKA Biosciences (Inst); Exelis (Inst); Exelis (Inst); Fore Biotherapeutics (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); Jazz Pharmaceuticals (Inst); K-Group Beta (Inst); Lantern Pharma (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); PharmaMar (Inst); Pionyr (Inst); PureTech (Inst); Qurgen Inc. (Inst); Sellas Life Sciences (Inst); Shanghai Huaota Biopharmaceutical (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Tigermed Group (Inst); TransCode Therapeutics, Inc. (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)
 
Angeles Alvarez Secord
Leadership - GOG Foundation; GOG Foundation; NRG Oncology (Inst); Project Nana Medical Advisory Board
Stock and Other Ownership Interests - Amgen; Johnson & Johnson/Janssen
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo; Foundation Medicine; Foundation Medicine; Genmab; Gilead Sciences; GlaxoSmithKline; Histosonics; Medtronic; Merck
Research Funding - Abbvie (Inst); Aravive (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); I-Mab (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mersana (Inst); Myriad Pharmaceuticals (Inst); OncoQuest Pharmaceuticals (Inst); Torl Biotherapeutics (Inst); Zentalis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate Author Royalty
Other Relationship - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Genmab; OncoQuest Pharmaceuticals; Roche/Genentech/Foundation Medicine
 
Cara Mathews
Consulting or Advisory Role - Abbvie; Daiichi Sankyo/Astra Zeneca; Repare Therapeutics
Research Funding - AADI (Inst); Abbvie; Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); avenge bio (Inst); Context Therapeutics; Debiopharm Group; Deciphera (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Genmab (Inst); Immunogen (Inst); Laekna Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novocure; Pfizer (Inst); ProfoundBio; Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro/GSK (Inst); Volastra Therapeutics (Inst); Zentalis (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; GOG Partners
 
Premal Thaker
Stock and Other Ownership Interests - Immunon
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Caris Life Sciences; Corcept Therapeutics; Eisai; GlaxoSmithKline; Immunogen; Immunon; Iovance Biotherapeutics; Merck; Mural Oncology; Novocure; Verastem/Pharmacyclics; Zentalis
Research Funding - GlaxoSmithKline (Inst); Merck (Inst)
 
Stephanie Blank
Leadership - America Board of Obstetrics and Gynecology
Research Funding - Acrivon Therapeutics (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); NX Development Corp. (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Zentalis (Inst)
 
Bradley Corr
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca/Merck (Inst); BioNTech SE (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo/Lilly (Inst); Eisai (Inst); GlaxoSmithKline (Inst)
Research Funding - Abbvie (Inst); NCI (Inst)
(OPTIONAL) Uncompensated Relationships - Genmab; Gilead Sciences
 
Yong Sang Song
No Relationships to Disclose
 
Zivko Vranjes
No Relationships to Disclose
 
Catherine Lee
Employment - Zentalis
 
Dongliang Zhuang
Employment - Zentalis
 
Thejonatha Annareddy
Employment - Zentalis
 
Naomi Molloy
Employment - Zentalis
 
C. Matthias Wilk
Employment - Zentalis
 
Joyce Liu
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Cullinan Oncology; Daiichi Sankyo; Eisai; Genmab; GlaxoSmithKline; LoxoLilly; Merck; Revolution Medicines; Systimmune; Zentalis
Research Funding - Aravive (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); NextCure (Inst); Pfizer (Inst); Pheon (Inst); Regeneron (Inst); Systimmune (Inst); Zentalis (Inst)